Efficacy and safety of ADC combined with PD-1 inhibitors versus GC regimen in neoadjuvant therapy for bladder cancer

Hu Xiao; Mei Yuhua; Li Li; Gou Xin

doi:10.13406/j.cnki.cyxb.003515

您当前的位置：

首页 >

文章列表页 >

Efficacy and safety of ADC combined with PD-1 inhibitors versus GC regimen in neoadjuvant therapy for bladder cancer

Urinary system tumors | 更新时间：2025-10-22

- Efficacy and safety of ADC combined with PD-1 inhibitors versus GC regimen in neoadjuvant therapy for bladder cancer
- Journal of Chongqing Medical University Vol. 49, Issue 6, Pages: 755-759(2024)
- 作者机构：
  
  重庆医科大学附属第一医院泌尿外科，重庆 400016
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003515
  CLC： R737.1
- Received：13 March 2024，
  
  Revised：2024-05-07，
  
  Accepted：22 May 2024，
  
  Published：28 June 2024
- 稿件说明：
移动端阅览
胡潇,梅宇华,李利,等.ADC联合PD-1抑制剂对比GC方案在膀胱癌新辅助治疗中的疗效及安全性研究[J].重庆医科大学学报,2024,49(6):755-759.

Hu Xiao,Mei Yuhua,Li Li,et al.Efficacy and safety of ADC combined with PD-1 inhibitors versus GC regimen in neoadjuvant therapy for bladder cancer[J].Journal of Chongqing Medical University,2024,49(6):755-759.
胡潇,梅宇华,李利,等.ADC联合PD-1抑制剂对比GC方案在膀胱癌新辅助治疗中的疗效及安全性研究[J].重庆医科大学学报,2024,49(6):755-759. DOI： 10.13406/j.cnki.cyxb.003515.

Hu Xiao,Mei Yuhua,Li Li,et al.Efficacy and safety of ADC combined with PD-1 inhibitors versus GC regimen in neoadjuvant therapy for bladder cancer[J].Journal of Chongqing Medical University,2024,49(6):755-759. DOI： 10.13406/j.cnki.cyxb.003515.

摘要

目的

分析真实世界中抗体偶联药物（antibody–drug conjugates，ADC）联合程序性死亡受体1（programmed cell death 1，PD-1）抑制剂在膀胱癌新辅助治疗中的疗效和安全性。

方法

回顾性纳入2017年8月至2023年12月于重庆医科大学附属第一医院接受ADC联合PD-1抑制剂和吉西他滨/顺铂（Gemcitabine/Cisplatin，GC）方案新辅助治疗的29例膀胱癌患者，分为 A 组（维迪西妥单抗联合替雷利珠单抗）和B组（吉西他滨联合顺铂），对比分析 2 组患者的病理完全缓解率（pathological complete response，pCR）和病理降期率，同时评估用药期间患者所发生的不良事件（adverse events，AEs）。

结果

A组共纳入17例患者，其中13例行膀胱根治切除术，4例选择保膀胱手术，B组共纳入12例患者，均行膀胱根治切除术。A组pCR为41.2%，B组的pCR为25.0%，

=0.449；A组的病理降期率为58.8%，B组的病理降期率为50.0%，

=0.716。A组中常见的AEs包括肝功能异常10例（58.8%），外周感觉神经功能减退8例（47.1%），贫血7例（41.2%）等，其中3～4级AEs共6例（35.3%）。B组中常见的 AEs包括贫血9例（75%），中性粒细胞减少8例（66.7%），恶心8例（66.7%）等，其中3～4级AEs共3例（25.0%）。

结论

在膀胱癌新辅助治疗中，ADC（维迪西妥单抗）联合PD-1抑制剂（替雷利珠单抗）较传统的GC方案具有更高的pCR和病理降期率，同时安全性可控，在人类表皮生长因子2阴性的患者中也有较好的疗效。

Abstract

Objective

To analyze the efficacy and safety of antibody-drug conjugates（ADCs） combined with programmed cell death 1（PD-1） inhibitors in neoadjuvant therapy for bladder cancer in real-world settings.

Methods

A retrospective study was conducted on 29 patients with bladder cancer who received ADC combined with PD-1 inhibitors or gemcitabine/cisplatin as neoadjuvant therapy at The First Affiliated Hospital of Chongqing Medical University between August 2017 and December 2023. The patients were divided into Group A（disitamab vedotin combined with atezolizumab） and Group B（gemcitabine combined with cisplatin）. The pathological complete response rate and pathological downstaging rate were compared between the two groups. The adverse events that occurred during treatment were evaluated.

Results

Group A included 17 patients，among whom 13 patients underwent radical cystectomy，and 4 patients opted for bladder-preserving surgery. Group B included 12 patients，all of whom underwent radical cystectomy. The pathological complete response rate was 41.2% in Group A and 25.0% in Group B（

=0.449）. The pathological downstaging rate was 58.8% in Group A and 50.0% in Group B（

=0.716）. Common adverse events in Group A included abnormal liver function（10 cases，58.8%），peripheral sensory neuropathy（8 cases，47.1%），and anemia（7 cases，41.2%），with 6 cases（35.3%） experiencing grade 3-4 AEs. In Group B，common adverse events included anemia（9 cases，75%），neutropenia（8 cases，66.7%），and nausea（8 cases，66.7%），with 3 cases（25.0%） experiencing grade 3-4 adverse events.

Conclusion

In neoadjuvant therapy for bladder cancer，ADC（disitamab vedotin） combined with PD-1 inhibitor（atezolizumab） has higher pathological complete response rate and pathological downstaging rate compared to the traditional gemcitabine/cisplatin regimen. Additionally，its safety profile is manageable，and it demonstrates good efficacy in human epidermal growth receptor 2-negative patients.

关键词

Keywords

references

Babjuk M ， Böhle A ， Burger M ， et al . EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder：update 2016 [J ] . Eur Urol ， 2017 ， 71 （ 3 ）： 447 - 461 ．

Sung H ， Ferlay J ， Siegel RL ， et al . Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2021 ， 71 （ 3 ）： 209 - 249 ．

Bhanvadia SK . Bladder cancer survivorship [J ] . Curr Urol Rep ， 2018 ， 19 （ 12 ）： 111 ．

Witjes JA ， Bruins HM ， Cathomas R ， et al . European association of urology guidelines on muscle-invasive and metastatic bladder cancer：summary of the 2020 guidelines [J ] . Eur Urol ， 2021 ， 79 （ 1 ）： 82 - 104 ．

Stecca C ， Abdeljalil O ， Sridhar SS . Metastatic Urothelial Cancer：a rapidly changing treatment landscape [J ] . Ther Adv Med Oncol ， 2021 ， 13 ： 17588359211047352 ．

Grossman HB ， Natale RB ， Tangen CM ， et al . Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [J ] . N Engl J Med ， 2003 ， 349 （ 9 ）： 859 - 866 ．

Yin M ， Joshi M ， Meijer RP ， et al . Neoadjuvant chemotherapy for muscle-invasive bladder cancer：a systematic review and two-step meta-analysis [J ] . Oncologist ， 2016 ， 21 （ 6 ）： 708 - 715 ．

Collaboration ABCMA . Neoadjuvant chemotherapy in invasive bladder cancer：update of a systematic review and meta-analysis of individual patient data advanced bladder cancer（ABC） meta-analysis collaboration [J ] . Eur Urol ， 2005 ， 48 （ 2 ）： 202 - 205 ；discussion 205-206．

Kapoor A ， Niazi T ， Noonan K ， et al . 2022 American Society of Clinical Oncology（ASCO） Genitourinary Cancers Symposium：meeting highlights [J ] . J De L’association Des Urol Du Can ， 2022 ， 16 （ 4 ）： 125 - 131 ．

van Dijk N ， Gil-Jimenez A ， Silina K ， et al . Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer：the NABUCCO trial [J ] . Nat Med ， 2020 ， 26 （ 12 ）： 1839 - 1844 ．

Li L ， Xu MZ ， Wang L ， et al . Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery [J ] . Eur Rev Med Pharmacol Sci ， 2020 ， 24 （ 24 ）： 12929 - 12937 ．

Flaig TW ， Spiess PE ， Abern M ， et al . NCCN guidelines ® insights：bladder cancer，version 2.2022 [J ] . J Natl Compr Canc Netw ， 2022 ， 20 （ 8 ）： 866 - 878 ．

Trifanescu OG ， Gales LN ， Paun MA ， et al . Long-term outcome of patients with stage Ⅱ and Ⅲ muscle-invasive urothelial bladder cancer after multimodality approach. which is the best option? [J ] . Medicina ， 2022 ， 59 （ 1 ）： 50 ．

Miyagi H ， Kwenda E ， Ramnaraign BH ， et al . Predicting complete response to neoadjuvant chemotherapy in muscle-invasive bladder cancer [J ] . Cancers ， 2022 ， 15 （ 1 ）： 168 ．

Roviello G ， Catalano M ， Santi R ， et al . Neoadjuvant treatment in muscle-invasive bladder cancer：from the beginning to the latest developments [J ] . Front Oncol ， 2022 ， 12 ： 912699 ．

Galsky MD ， Pal SK ， Chowdhury S ， et al . Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate，vinblastine，doxorubicin，plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer [J ] . Cancer ， 2015 ， 121 （ 15 ）： 2586 - 2593 ．

von der Maase H ， Sengelov L ， Roberts JT ， et al . Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin，with methotrexate，vinblastine，doxorubicin，plus cisplatin in patients with bladder cancer [J ] . J Clin Oncol ， 2005 ， 23 （ 21 ）： 4602 - 4608 ．

Vale C . Neoadjuvant chemotherapy in invasive bladder cancer：a systematic review and meta-analysis [J ] . Lancet ， 2003 ， 361 （ 9373 ）： 1927 - 1934 ．

Birrer MJ ， Moore KN ， Betella I ， et al . Antibody-drug conjugate-based therapeutics：state of the science [J ] . J Natl Cancer Inst ， 2019 ， 111 （ 6 ）： 538 - 549 ．

Coats S ， Williams M ， Kebble B ， et al . Antibody-drug conjugates：future directions in clinical and translational strategies to improve the therapeutic index [J ] . Clin Cancer Res ， 2019 ， 25 （ 18 ）： 5441 - 5448 ．

Rose TL ， Harrison MR ， Deal AM ， et al . Phase Ⅱ study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer [J ] . J Clin Oncol ， 2021 ， 39 （ 28 ）： 3140 - 3148 ．

Rodriguez-Moreno JF ， de Velasco G ， Bravo Fernandez I ， et al . Impact of the combination of durvalumab（MEDI4736） plus olaparib（AZD2281） administered prior to surgery in the molecular profile of resectable urothelial bladder cancer：NEODURVARIB Trial [J ] . J Clin Oncol ， 2020 ， 38 （ 6_suppl ）： 542 ．

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research advances in liquid biopsy for bladder cancer

Construction of a model for bladder cancer prognosis and immune analysis based on m6A-related long non-coding RNAs

Current development of wireless capsule cystoscope

Comparison of the clinical efficacy of Disitamab Vedotin and postoperative chemotherapy in the treatment of HER-2 positive locally advanced urothelial carcinoma

Value of inflammatory biomarkers in predicting the outcome of patients with muscle-invasive bladder cancer receiving different neoadjuvant treatment regimens

Related Author

Zhang Bingnan

Liu Peihua

Fan Benyi

Yu Haitao

Mei Yuhua

Li Li

Chen Hua

He Weiyang

Related Institution

Department of Urology，Xiangya Hospital，Central South University/National Clinical Research Center for Geriatric Disorders

Department of Thoracic Surgery，The Second Affiliated Hospital of Air Force Medical University

Department of Geriatrics, Xijing Hospital, Air Force Medical University

Department of Urology,the First Affiliated Hospital of Chongqing Medical University

重庆医科大学核医学科

⁰